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ABSTRACT:
Pharmacokinetics of caffeine have been studied in sheep and
cattle treated with caffeine (5 mg/kg) by intravenous injection.
Terminal-phase elimination half-lives were 8.9 hr In sheep and 8.1
hr in cattle. Noncompartmental analyses of data collected from
individual animals indicate that neither terminal-phase rate con-
slants (13) nor mean residence times of caffeine in plasma differed
between species. Each of the three possible N-demethylated pn-
mary metabolites of caffeine was detected in plasma from each
species, with theophylllne predominating in sheep and paraxan-
thine predominating in cattle. These data indicate that hepatic
capacity to clear caffeine from the systemic circulation is similar
between sheep and cattle, but that the preferred routes of metab-
olism differ. Expression of cytochromes P4501A (CYPIA subfamily)
may differ between these species.
Hepatic metabolism of many drugs and xenobiotics critically in-
volves the CYP’ superfamily of enzymes, and dealkylation of various
7-alkoxyresorufin homologs has been proposed to reflect activities of
several CYP subtypes (1, 2). For example, deethylation of
7-ethoxyresorufin has been related to CYPIA enzymes, although
specific association with CYP1A1 or CYP1A2 isoenzymes may be
species-dependent (3-5). Using this substrate, and noninduced hepa-
tocytes, Van’t Klooster et a!. (6) have studied this reaction and have
determined a less active deethylation process in hepatocytes from
sheep than from cattle or goats. To determine whether this observation
reflects a species difference between sheep and cattle, we have studied
the in vivo pharmacokinetics and demethylation of caffeine, an alter-
nate CYP1A substrate.
Caffeine (l,3,7-trimethylxanthine) is metabolized by hepatic CYP
enzymes to four primary metabolites: 1,3-dimethylxanthine (theoph-
ylline), 1,7-dimethylxanthine (paraxanthine), 3,7-dimethylxanthine
(theobromine), and 1,3,7-trimethyluric acid. Its clearance from plasma
is thought to reflect hepatic metabolic capacity (7). N-Demethylation
of caffeine also seems to involve enzymes of the CYP1A subfamily
(8-10) and N-3 demethylation, to paraxanthine, has been applied as a
specific index of CYPIA2 activity (1 1-13).
Materials and Methods
Chemicals. Authentic samples of caffeine, its demethyl metabolites and
7-(-hydroxyethyl)-theophyl1ine were purchased from Aldrich Chemical
Company, Inc. (Milwaukee, WI). Solvents were HPLC grade and were pur-
chased from BDH Chemicals (Vancover, British Columbia, Canada). Solutions
of caffeine or each metabolite were prepared in water containing an equimolar
amount of sodium benzoate.
Animals. Three Suffolk ewes (body weights, 74-107 kg) and three Here-
This study was supported by the Canada Alberta Livestock Research Trust,
Inc.
1 Abbreviations used are: CYP, cytochrome P450; CYP1A, cytochrome
P4501A; CYP1A1 , cytochrome P4501A1 ; CYP1A2, cytochrome P4501A2; t1,,
elimination half-life; MAT, mean residence time; CL8, systemic clearance; V,
volume at steady state.
ford heifers (body weights, 264-290 kg) were provided by the Canada Alberta
Livestock Research Trust, Inc. (Lethbridge, Alberta, Canada). Sheep were
maintained on alfalfa/grass hay and cattle were maintained on cubed alfalfa.
Animal Treatments. On treatment mornings, cannulae were placed into the
left and right external jugular veins of sheep or cattle. Filter-sterilized solutions
of caffeine (sheep, 20 mg/ml; cattle, 50 mg/mi) were injected rapidly through
the left cannula to a final dose of 5 mg/kg. Samples of blood were drawn into
heparinized vacutainers (Becton Dickinson Vacutainer Systems, Rutherford,
NJ) through the right cannula at 30, 60, 90, 120, 150, 180, 240, 300, 360, 420,
and 1440 mm after treatment. Blood was centrifuged, and plasma was stored
at -40#{176}Cuntil analysis.
Preparation of internal Standard: 7-(-Hydroyethyl)-theophylline Ac-
etate. Under the chromatographic conditions adopted, an endogenous compo-
nent of cattle plasma eluted simultaneous to 7-(f3-hydroxyethyl)-theophylline.
To achieve separation, an internal standard was prepared by acetylation of
7-(-hydroxyethyl)-theophylline at room temperature with acetic anhydride/
pyridine in acetonitrile solvent. Evaporation of solvent and recrystallization
from methanol afforded 7-(3-hydroxyethy1)-theophylline acetate [m.p. 104#{176}C,
lit. m.p. 105#{176}C(14)]. This product chromatographed as a single peak by HPLC
and capillary column GC. Mass spectral analysis was consistent with 7-(3-
hydroxyethyl)-theophylline acetate.
Standard Solutions and Standard Curves. Stock solutions of caffeine and
metabolites (1 mg/ml) were prepared in distilled water containing sodium
benzoate (1 mg/ml). Working solutions were prepared by dilution of stock
solutions into acetonitrile (0.1 or 0.01 mg/mI). Standard curve (0.1, 0.5, 1.0,
5.0, 10.0, and 12.5 j.g/ml) and quality control (0.1 and 0.5 g/ml) samples
were prepared in duplicate, on each analysis day, by addition of exact volumes
of working solutions to plasma (1 .0 ml) previously drawn from a representative
animal of the species being studied. These samples were assayed each day in
parallel to unknown samples.
Analysis of Caffeine and Its N-demethylated Metabolites. Caffeine and
its N-demethylated metabolites were extracted from plasma, and analyzed by
HPLC as described by Haughey et a!. (15), except that a C8 rather than a C18
column was used, and the volume of plasma employed was 1 ml. Briefly,
samples of plasma (1 ml) were transferred into borosilicate screw cap tubes
(P’FFE-lined caps). Hydrochloric acid (0.1 ml, 1.0 N) and internal standard (5
!.Lg/ml) were added. Analytes were extracted by gentle shaking (15 mm) with
chloroform/2-propanol (4:1, 2 X 5 ml). Organic layers were evaporated under
a gentle stream of nitrogen, and residues were reconstituted into the mobile
phase (1 ml). Twenty-microliter portions were injected onto the HPLC column.
Chromatography. Caffeine and its metabolites were resolved by isocratic
HPLC with a Waters HPLC system equipped with a 712-WISP autosampler,
a C8 column (Zorbax RX-C8, 25 X 0.46 cm, 3 im particle size), and a model
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maintained at 30#{176}C.The mobile phase was prepared by diluting a mixture of
acetonitrile and phosphoric acid (130 ml + 0.5 ml) with HPLC-grade water
(869.5 ml). Solvent flow rate was 1.0 ml/min. Amounts of caffeine in unknown
samples were determined by linear regression analysis of unknown and stan-
dard sample caffeine/internal standard peak area ratios.
Pharmacokinetics. Plasma concentration-time data from sheep and cattle
were fitted to mono- and biexponential equations (PCNONLIN 4.2, SCI
Software, Lexington, KY). Goodness-of-fit, as determined from Akaike’s
Information Criteria (16), supported use of a biexponential equation to predict
theoretical plasma concentrations at zero time. Plasma concentration-time data,
including predicted concentrations at time 0, were then analyzed according to
noncompartmental techniques. Values of pharmacokinetic parameters were
calculated according to standard equations (17) and are reported as means ±
SD. Differences between sheep and cattle in parameter-calculated values were
examined by Welch’s t test (GraphPad Instat, version 2.04a, GraphPad Soft-
ware, San Diego, CA). Statistical significance was assigned at p < 0.05.
Identification of Metabolites in HPLC Chromatograms. Chromato-
graphic peaks corresponding to dimethylxanthine metabolites of caffeine were
identified in HPLC chromatograms of plasma extracts by comparison of
retention times to authentic samples of each metabolite. In addition, samples of
plasma (1 ml) collected from caffeine-treated animals were augmented with
each dimethylxanthine metabolite and then assayed. Area counts of chromato-
graphic peaks, before and after spiking, were compared to determine specific
augmentation.
Results
Recoveries from cattle plasma of caffeine (1 g/ml), and of the
internal standard (5 aWml), were 77.3 ± 5.8 and 71 . 1 ± 3.6%
(means ± SD, N 6), respectively. Validation samples prepared in
cattle plasma (0.5, 1.0, or 10.0 .ag/ml caffeine, N = 6) were assayed
to contain 0.550 ± 0.018, 1.04 ± 0.09, and 10.15 ± 0.85 ,.g/ml.
Cattle plasma validation samples (N = 3) containing 2.0 p.g/ml of
each metabolite were determined to contain 1.98 ± 0.06 .tg/ml
theobromine, 1.98 ± 0.06 p.g/ml paraxanthine, or 2.02 ± 0.07 .ag/ml
theophylline. Recovery of the dimethylxanthine metabolites from
cattle plasma ranged between 85 and 95%. Standard curves, prepared
in either sheep or catfie plasma, were linear over the concentration
range from 0.1 to 12.5 tag/mi (r = 0.995-0.999). Quality control
samples (0.5 or 1.0 g/ml caffeine) run daily, in parallel to unknown
samples, were assayed to contain 0.53 ± 0.07 and 1.00 ± 0.07 pg/mi
(N = 16) from sheep plasma and 0.53 ± 0.06 and 1 .05 ± 0.08 pg/mi
(N = 16) from cattle plasma.
HPLC chromatograms of extracts of blank and augmented (1 g/
ml) control cattle plasma and of plasma from representative sheep and
cattle (300 mm posttreatment) are shown in fig. 1. These chromato-
grams indicate that each of the three possible dimethyixanthine me-
tabolites of caffeine were present in the plasma of sheep and cattle,
and that the relative amounts varied between species. Augmentation
experiments and retention time comparisons indicated that theophyl-
line was the major metabolite in sheep plasma, whereas in cattle
plasma the major metabolite was paraxanthine.
Plots of mean concentrations of caffeine in plasma collected from
treated sheep and cattle are shown in fig. 2. Values of pharmacoki-
netic parameters as determined by noncompartmental techniques are
listed in table 1. These data indicate that, whereas the t112 and MRT
of caffeine in plasma did not differ significantly between sheep and
cattle, values for CL5 and V may be slightly smaller in sheep than in
cattle (p < 0.05).
Amounts of theophylline in sheep plasma and of paraxanthine in
cattle plasma after treatment with caffeine are indicated in fig. 3.
Maximum concentrations were -1 ag/ml, 360-420 mm after treat-
ment. Levels of theobromine and paraxanthine in sheep plasma, or of
theobromine and theophylline in cattle plasma were generally below
0.2 .ag/ml and are not illustrated.
-
0 5 10 15 20 25 30 35
RETENTION TIME (mm)
FiG. 1. HPLC chromatograms ofplasma from cattle [(a) blank; (b)
theobromine (TB), paraxanthine (PX), theophy!line (TP), and caffeine
(CA)-each 1 pg/ml; and (c) 3tX-min posttreatmentJ and sheep 1(d) 300-
mm posttreatmentJ.
IS, internal standard, 5 g/ml.
MINUTES
FIG. 2. Caffeine in plasma from sheep (curve a) and cattle (curve b) after
intravenous injection of caffeine (5 mg/kg, N 3; means ± SD).
Mean concentrations of caffeine and each dimethyixanthine metab-
olite in plasma collected 300 mm after treatment, plus paraxanthine/
caffeine and dimethylxanthine ratios, are indicated in table 2.
Discussion
It has been suggested that hepatocytes from food-producing species
may have application in the determination of metabolite patterns of
veterinary drugs and crop protection chemicals (18, 19). However,
although many food-producing species are ruminants, the bulk of data
regarding the metabolism of xenobiotics has been collected in non-
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TABLE I TABLE 2
AUC, area under the zero-moment concentration in plasma/time curve.




FIG. 3. Theophylline in plasma from sheep (curve a) and paraxanthine in
plasma from cattle (curve b) after intravenous injection of caffeine (5 mg/
kg, N 3; means ± SD).
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Pharmacokinetics of caffeine in sheep and cattle plasma after treatment by





(min) 0.0013 ± 0.0003 0.0014 ± 0.0001
tI/2j3 535 mm 485 mm
(8.9 hr) (8.1 hr)
AUC
(g/mVmin) 6330 ± l950’ 3690 ± 545
MRT
(mm) 700 ± 170 590 ± 65
CL,,
(ml/min/kg) 0.8 ± 0.2a 1.4 ± 0.2
V’s
(mI/kg) 560 ± 50#{176} 805 ±90
ruminant species. Application of these observations to ruminant mod-
els may be complicated by in vitro observations of differences among
ruminant species regarding relative activities of CYP1A enzymes (6).
The goal of our experiments was therefore to determine the CL5 and
metabolite patterns of an innocuous CYP1A substrate in ruminant
species, in vivo. Caffeine was chosen as a test compound, because its
metabolism by other species is well known, both in vivo and in vitro,
and reports exist regarding the association of CYP1A isoenzymes
with its metabolic transformations (8-12).
Our results suggest that CL5 of caffeine in sheep (0.8 ± 0.2
mi/mn/kg) and cattle (1.4 ± 0.2 mI/mn/kg) occurred at rates similar
to those observed in several other nonruminant species, such as dogs
(1-2.5 ml/min/kg)(20) and people (1.0 mI/mn/kg) (15). The t,’s of
caffeine in sheep (8.9 hi) and cattle (8. 1 hr) were also similar to those
in dogs (3.2-5.2 hr) (21), people (6.5 1w) (15), or horses (6.6 hr) (22);
and the MRT of caffeine in sheep and cattle was similar to that
reported in dogs (20). These comparisons of the pharmacokinetics of
caffeine among sheep, cattle, and other species suggest that, as in
those other species, caffeine behaves as a capacity-limited drug and
Mean concentrations (g/ml ± SD) of caffeine and each dimethyLranthine
metabolite in the plasma of sheep and cattle (N 3) 300 mm after
intravenous injection of caffeine (5 mg/kg)
Analyte Sheep Cattle
Caffeine 5.2 ± 1.0 3.1 ± 0.2
Paraxanthine 0.15 ± 0.10 0.70 ± 0.10
Theophylline 0.89 ± 0.29 0.15 ± 0.01
Theobromine 0. 19 ± 0.01 0. 12 ± 0.01




a TB, theobromine; PX, paraxanthine; TP, theophylline.
that its rate of elimination from plasma may be a useful index of
hepatic capacity.
Caffeine was converted metabolically to three dimethylxanthines
(theophylline, paraxanthine, and theobromine) by sheep or cattle,
although the predominant demthylated metabolite differed from the-
ophylline in sheep to paraxanthine in cattle. Evidence from in vitro
studies suggests that these primary metabolites are formed from
caffeine by CYP enzymes and that the pattern of metabolite formation
may indicate expression of CYP1A1/CYP1A2 isoenzymes (8-12). In
people, constitutive expression of CYP1A2 exceeds that of CYP1A1,
and caffeine is metabolized predominantly to paraxanthine (8, 11, 12).
However, in cynomolgus monkeys (Macaca fasicularis), expression
of either isoenzyme is low and the predominating demethylation of
caffeine is to theophylline (8, 23, 24), probably by other CYP en-
zymes. In that vein, Berthou et a!. (8) reported that, whereas parax-
anthine accounted for 81 % in human liver microsomes, theophylline
accounted for 89% of total dimethylxanthines produced by cynomol-
gus monkey liver microsomes. This pattern of in vitro demethylation
is similar to our current in vivo situation, wherein 300 mm after
treatment, theophylline accounted for 72% of total climethylxanthine
in plasma from sheep and paraxanthine accounted for 76% of the total
in cattle.
Fuhr and Rost (1 1) further suggest that, in people, the ratio of
paraxanthine to caffeine in plasma, 5-7 hr after treatment, is a reliable
and specific indicator of CYP1A2 activity in vivo. Our experiments
indicate this ratio to be 0.03 in sheep and 0.23 in cattle (table 2),
suggesting that, in comparison with cattle, sheep may less actively
express the CYP1A2 isoenzyme. This interpretation is consistent with
prior observations of lower 7-ethoxyresorufin-O-deethylation by
hepatocytes of sheep than of cattle or goats (6). Additional in vivo or
in vitro experiments with other known CYP1A2 substrates, such as
phenacetin (25), are required to test this difference more clearly.
Evidence indicates that CYP1A2 enzyme contributes to the metab-
olism of a wide variety of chemicals and drugs, including phenacetin
(25), verapamil (26), propaphenone (27), and clozapine (28), as well
as the bioactivation of aflatoxin-Bl (29, 30) and many carcinogenic
arylamines (31, 32). If confirmed, decreased CYP1A (or CYP1A2)
activity in sheep livers may contribute to an interspecies variation in
the metabolism of agricultural and veterinary xenobiotics.
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